Macrab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed to manage gastrointestinal disorders characterized by acid-related symptoms and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcer disease. The combined action of Domperidone and Rabeprazole in Macrab-DSR Capsule offers symptomatic relief by reducing acid secretion while enhancing gastric motility, improving patient outcomes in acid peptic disorders. This formulation is typically prescribed for short-term management of GERD with associated motility dysfunction and should be used under medical supervision. Contraindications include known hypersensitivity to either component, and caution is advised in patients with cardiac arrhythmias or prolonged QT interval due to Domperidone’s potential cardiac effects. Macrab-DSR Capsule is administered orally, preferably before meals, and dosage adjustments should be individualized based on clinical response and tolerability.